Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

@article{Cipriani2009ComparativeEA,
  title={Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis},
  author={Andrea Cipriani and Toshiaki Furukawa and Georgia Salanti and John R. Geddes and Julian P. T. Higgins and Rachel Churchill and Norio Watanabe and Atsuo Nakagawa and Ichiro M. Omori and Hugh McGuire and Michele Tansella and Corrado Barbui},
  journal={The Lancet},
  year={2009},
  volume={373},
  pages={746-758}
}
BACKGROUND Conventional meta-analyses have shown inconsistent results for efficacy of second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression. METHODS We systematically reviewed 117 randomised controlled trials (25 928 participants) from 1991 up to Nov 30, 2007, which compared any of the following antidepressants at… Expand
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
TLDR
Overall, antipsychotic drugs were significantly more effective than mood stabilisers, and haloperidol should be considered as among the best of the available options for the treatment of manic episodes. Expand
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
TLDR
A protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression is presented. Expand
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
TLDR
Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression, but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects. Expand
Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis
TLDR
Compared with other drugs, TCAs and SSRIs have the most solid evidence base for being effective in the primary care setting, but the effect size compared with placebo is relatively small. Expand
Comparative effi cacy and tolerability of antidepressants for major depressive disorder in children and adolescents : a network meta-analysis
Methods We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS,Expand
P-1102 - Comparative Effectiveness of Second Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
TLDR
The existing evidence does not warrant the choice of one second-generation antidepressant over another based on greater efficacy and effectiveness, and no substantial differences in efficacy could be detected among second- generation antidepressants. Expand
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
TLDR
This work aimed to update and expand previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder, and found that all antidepressants were more effective than placebo. Expand
Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis
TLDR
A protocol for a network meta-analysis aimed at extending results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults is presented. Expand
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
TLDR
As a second-line treatment drug, escitalopram was suggested to be non-inferior to duloxetine in acceptability. Expand
Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model
TLDR
Of the investigated antidepressants, escitalopram has the highest probability of remission and is the most effective and cost-effective pharmacological treatment in a primary care setting, when evaluated over a one year time-horizon. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 160 REFERENCES
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
TLDR
A systematic review and meta-analysis of comparative evidence for 6 SSRIs and 4 other second-generation antidepressants is conducted, examining the role of these agents in the initial treatment of ambulatory adult patients with major depressive disorder. Expand
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
TLDR
Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants, and further studies are required to determine the clinical importance of this finding. Expand
Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
TLDR
Although there was a numerical advantage for sertraline on several efficacy measures, there was no statistically significant difference found between the treatment groups. Expand
Are all antidepressants really the same? The case of fluoxetine: a systematic review.
TLDR
This systematic review highlighted that there are differences between fluoxetine and specific comparator antidepressants, and the statistical approach adopted could represent a useful tool for putting clinical trial data into practice. Expand
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder
TLDR
A double-blind, randomized clinical trial was performed in which general practitioners and psychiatrists compared fixed doses of escitalopram with citaloprams over 8 weeks in outpatients with major depressive disorder (MDD) and confirmed that escITALopram has a superior effect in MDD. Expand
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
TLDR
Both mirtazapine and fluoxetine were indistinguishable in effectiveness for treatment of depressive symptoms, and both were well tolerated by the population of depressed Chinese patients. Expand
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*
TLDR
Both duloxetine and escitalopram showed significantly greater improvement on the primary efficacy measure than placebo over the 8‑week acute treatment period, while no differences were observed between drugs or between drugs and placebo on response and remission rates at 8 weeks. Expand
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
TLDR
Although the magnitude of global changes in depression, anxiety, and quality of life was larger with sertraline than fluoxetine, none of the between-group differences reached statistical significance, and sERTraline was associated with significantly superior performance on the Leeds Sleep Evaluation scale and on SIP items relating to sleep and rest, emotional behaviour and ambulation. Expand
Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline
  • S. Stahl
  • Medicine, Psychology
  • Biological Psychiatry
  • 2000
TLDR
This study confirms the antidepressant efficacy of two SSRIs, citalopram and sertraline, as confirmed in a placebo-controlled comparison of the antidepressant effects of twoSSRIs. Expand
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
  • A. Schatzberg, S. Roose
  • Psychology, Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
TLDR
There was no significant difference in efficacy among placebo, venlafaxine, and fluoxetine for the treatment of depression in depressed patients older than 65 years. Expand
...
1
2
3
4
5
...